Acrobiosystems Co

Acrobiosystems Co Current Assets

The Current Assets of Acrobiosystems Co (301080.SZ) as of Nov 11, 2026 is 290.96 M CNY. In the previous year, Current Assets was 373.15 M CNY — a change of -22.03% (lower).

Current Assets

290.96 MCNY

YoY

-22.03%

Last updated:

Current Assets of Acrobiosystems Co is 2025 290.96 M CNY. Current Assets of Acrobiosystems Co was 2024 373.15 M CNY. It decreases by -22.03% lower compared to the previous year.

The Acrobiosystems Co Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
61.73 M CNY
Jan 1, 2019
38.47 M CNY
Jan 1, 2020
70.84 M CNY
Jan 1, 2021
119.91 M CNY
Jan 1, 2022
167.82 M CNY
Jan 1, 2023
255.06 M CNY
Jan 1, 2024
373.15 M CNY
Jan 1, 2025
290.96 M CNY
The Acrobiosystems Co Current Assets history
YEARCurrent AssetsYoY
290.96 MCNY-22.03%
373.15 MCNY+46.30%
255.06 MCNY+51.98%
167.82 MCNY+39.96%
119.91 MCNY+69.27%
70.84 MCNY+84.15%
38.47 MCNY-37.68%
61.73 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Current Assets of Acrobiosystems Co is 290.96 M CNY in 2025.

Current Assets of Acrobiosystems Co changed from 373.15 M CNY to 290.96 M CNY, representing a -22.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co